High ezrin expression was significantly associated with adverse survival of patients whose tumours were categorised as receptor (ER, PgR or HER2) positive (p < 0.001; Figure 2C) in comparison to those categorised as triple‐negative breast cancer (p = 0.889; Figure 2D). This evidence concerns the gene ERBB2 and neoplasm.